| 1 | half | 7,488 |
| 2 | one-third | 1,119 |
| 3 | doubling | 836 |
| 4 | two-thirds | 713 |
| 5 | one-half | 355 |
| 6 | one-quarter | 139 |
| 7 | one-fifth | 125 |
| 8 | three-quarters | 122 |
| 9 | one-fourth | 94 |
| 10 | halving | 51 |
| 11 | three-fourths | 39 |
| 12 | one-tenth | 30 |
| 13 | two-third | 25 |
| 14 | one-sixth | 20 |
| 15 | four-fifths | 17 |
| 16 | three-quarter | 10 |
| 17 | 40years | 8 |
| 18 | five-days | 8 |
| 19 | three-fifths | 8 |
| 20 | two-fifths | 8 |
| 21 | three-fourth | 7 |
| 22 | digestin | 5 |
| 23 | δcortisol | 5 |
| 24 | hydrovinylation | 4 |
| 25 | one-seventh | 4 |
| 26 | scientification | 4 |
| 27 | 1,3-dags | 3 |
| 28 | 15,346 | 3 |
| 29 | 15months | 3 |
| 30 | 26weeks | 3 |
| 31 | 3/4th | 3 |
| 32 | 3n+ | 3 |
| 33 | birth-weights | 3 |
| 34 | mistiming | 3 |
| 35 | re-reading | 3 |
| 36 | squandering | 3 |
| 37 | thermisation | 3 |
| 38 | 'about | 2 |
| 39 | 1.73-fold | 2 |
| 40 | 1.8g/l | 2 |
| 41 | 2/3rds | 2 |
| 42 | 2gr/day | 2 |
| 43 | 3,955 | 2 |
| 44 | 30µg/ml | 2 |
| 45 | circosan | 2 |
| 46 | recouping | 2 |
| 47 | tpmsc | 2 |
| 48 | 'distinction | 1 |
| 49 | -1/ | 1 |
| 50 | -12. | 1 |
| 51 | 0.1563 | 1 |
| 52 | 0.4μg/m | 1 |
| 53 | 0.6-0.8/1000/year | 1 |
| 54 | 1,200-2,000 | 1 |
| 55 | 1-4pw | 1 |
| 56 | 1.1mg/ml | 1 |
| 57 | 1.4-mg/dl | 1 |
| 58 | 1.545-3.523 | 1 |
| 59 | 1.5log10cycles | 1 |
| 60 | 1/1,000th | 1 |
| 61 | 1/20-1/30 | 1 |
| 62 | 1/40th | 1 |
| 63 | 100-190mgy | 1 |
| 64 | 10iu/ml | 1 |
| 65 | 10lb | 1 |
| 66 | 128,000 | 1 |
| 67 | 12:00-13:30 | 1 |
| 68 | 133mg/l | 1 |
| 69 | 14.6-fold | 1 |
| 70 | 144,000 | 1 |
| 71 | 14400 | 1 |
| 72 | 148°c | 1 |
| 73 | 171/187 | 1 |
| 74 | 18.34±4.36 | 1 |
| 75 | 1:13,500 | 1 |
| 76 | 1:9000 | 1 |
| 77 | 1°/year | 1 |
| 78 | 1½-fold | 1 |
| 79 | 2-5s | 1 |
| 80 | 2.1-mg/dl | 1 |
| 81 | 2.2mb | 1 |
| 82 | 2.5-5-fold | 1 |
| 83 | 2.5-to-1 | 1 |
| 84 | 20/1500 | 1 |
| 85 | 200-bite | 1 |
| 86 | 204/690 | 1 |
| 87 | 21day | 1 |
| 88 | 22-nucleotide | 1 |
| 89 | 22.2ghz/refractive-index-unit | 1 |
| 90 | 22mm | 1 |
| 91 | 24,680 | 1 |
| 92 | 250pgml | 1 |
| 93 | 27mm | 1 |
| 94 | 29000 | 1 |
| 95 | 2mm×5mm | 1 |
| 96 | 3-folds | 1 |
| 97 | 3-log-reduction | 1 |
| 98 | 3.5log10cycles | 1 |
| 99 | 300x10 | 1 |
| 100 | 3500bp | 1 |
| 101 | 37w | 1 |
| 102 | 3900-fold | 1 |
| 103 | 4.5months | 1 |
| 104 | 44.1-mb | 1 |
| 105 | 49,605 | 1 |
| 106 | 5-month-history | 1 |
| 107 | 5.4×10 | 1 |
| 108 | 500,000/microl | 1 |
| 109 | 54/146 | 1 |
| 110 | 5in | 1 |
| 111 | 5mgg | 1 |
| 112 | 6.0mmol | 1 |
| 113 | 60minutes | 1 |
| 114 | 62å | 1 |
| 115 | 6300-8400 | 1 |
| 116 | 6300-base | 1 |
| 117 | 7.0μgl | 1 |
| 118 | 74mbq | 1 |
| 119 | 9.3/1 | 1 |
| 120 | 9.6-times | 1 |
| 121 | 90/1000 | 1 |
| 122 | afterthoughts | 1 |
| 123 | ayu-nephro-tone | 1 |
| 124 | bisects | 1 |
| 125 | body/self | 1 |
| 126 | chews/all | 1 |
| 127 | co-signing | 1 |
| 128 | control/coping | 1 |
| 129 | coping/control | 1 |
| 130 | cuanzu | 1 |
| 131 | cytokines-of | 1 |
| 132 | deride | 1 |
| 133 | dose-proportionately | 1 |
| 134 | eight-times | 1 |
| 135 | eqalled | 1 |
| 136 | familiarities | 1 |
| 137 | gbp350 | 1 |
| 138 | glorify | 1 |
| 139 | groups.although | 1 |
| 140 | gut-representation | 1 |
| 141 | harm-fullness | 1 |
| 142 | insufflate | 1 |
| 143 | job-demand | 1 |
| 144 | kosta | 1 |
| 145 | lenghthening | 1 |
| 146 | limac | 1 |
| 147 | mean-2.0 | 1 |
| 148 | miserably | 1 |
| 149 | mr-images | 1 |
| 150 | new-users | 1 |
| 151 | nondissociable | 1 |
| 152 | nonrefrigerated | 1 |
| 153 | one-hundredth | 1 |
| 154 | one-thirds | 1 |
| 155 | one-thirtieth | 1 |
| 156 | phenytoin.for | 1 |
| 157 | placebo-this | 1 |
| 158 | placebo.sumatriptan | 1 |
| 159 | placebo.trials | 1 |
| 160 | pm-release | 1 |
| 161 | positions.as | 1 |
| 162 | pound18 | 1 |
| 163 | pseudo-doctoring | 1 |
| 164 | pseudorelationships | 1 |
| 165 | qualitatively.12 | 1 |
| 166 | qualitatively.9 | 1 |
| 167 | qualitatively.six | 1 |
| 168 | questions-including | 1 |
| 169 | rs1048943/cyp1a1 | 1 |
| 170 | salak | 1 |
| 171 | seven-tenths | 1 |
| 172 | some-of | 1 |
| 173 | st£12.38 | 1 |
| 174 | tanezumab+nsaids | 1 |
| 175 | test-positives | 1 |
| 176 | time-end-diastolic | 1 |
| 177 | ward-and | 1 |
| 178 | zncl2/hzsm-5 | 1 |
| 179 | £104 | 1 |
| 180 | £288,600 | 1 |
| 181 | £3,000 | 1 |
| 182 | £62,500 | 1 |
| 183 | £6200 | 1 |
| 184 | £830 | 1 |
| 185 | épidémiology | 1 |
| 186 | π/6 | 1 |
| 187 | €1100 | 1 |
| 188 | €68,000 | 1 |
| 1 | 'about | 2 |
| 2 | 'distinction | 1 |
| 3 | -1/ | 1 |
| 4 | -12. | 1 |
| 5 | 0.1563 | 1 |
| 6 | 0.4μg/m | 1 |
| 7 | 0.6-0.8/1000/year | 1 |
| 8 | 1,200-2,000 | 1 |
| 9 | 1,3-dags | 3 |
| 10 | 1-4pw | 1 |
| 11 | 1.1mg/ml | 1 |
| 12 | 1.4-mg/dl | 1 |
| 13 | 1.545-3.523 | 1 |
| 14 | 1.5log10cycles | 1 |
| 15 | 1.73-fold | 2 |
| 16 | 1.8g/l | 2 |
| 17 | 1/1,000th | 1 |
| 18 | 1/20-1/30 | 1 |
| 19 | 1/40th | 1 |
| 20 | 100-190mgy | 1 |
| 21 | 10iu/ml | 1 |
| 22 | 10lb | 1 |
| 23 | 128,000 | 1 |
| 24 | 12:00-13:30 | 1 |
| 25 | 133mg/l | 1 |
| 26 | 14.6-fold | 1 |
| 27 | 144,000 | 1 |
| 28 | 14400 | 1 |
| 29 | 148°c | 1 |
| 30 | 15,346 | 3 |
| 31 | 15months | 3 |
| 32 | 171/187 | 1 |
| 33 | 18.34±4.36 | 1 |
| 34 | 1:13,500 | 1 |
| 35 | 1:9000 | 1 |
| 36 | 1°/year | 1 |
| 37 | 1½-fold | 1 |
| 38 | 2-5s | 1 |
| 39 | 2.1-mg/dl | 1 |
| 40 | 2.2mb | 1 |
| 41 | 2.5-5-fold | 1 |
| 42 | 2.5-to-1 | 1 |
| 43 | 2/3rds | 2 |
| 44 | 20/1500 | 1 |
| 45 | 200-bite | 1 |
| 46 | 204/690 | 1 |
| 47 | 21day | 1 |
| 48 | 22-nucleotide | 1 |
| 49 | 22.2ghz/refractive-index-unit | 1 |
| 50 | 22mm | 1 |
| 51 | 24,680 | 1 |
| 52 | 250pgml | 1 |
| 53 | 26weeks | 3 |
| 54 | 27mm | 1 |
| 55 | 29000 | 1 |
| 56 | 2gr/day | 2 |
| 57 | 2mm×5mm | 1 |
| 58 | 3,955 | 2 |
| 59 | 3-folds | 1 |
| 60 | 3-log-reduction | 1 |
| 61 | 3.5log10cycles | 1 |
| 62 | 3/4th | 3 |
| 63 | 300x10 | 1 |
| 64 | 30µg/ml | 2 |
| 65 | 3500bp | 1 |
| 66 | 37w | 1 |
| 67 | 3900-fold | 1 |
| 68 | 3n+ | 3 |
| 69 | 4.5months | 1 |
| 70 | 40years | 8 |
| 71 | 44.1-mb | 1 |
| 72 | 49,605 | 1 |
| 73 | 5-month-history | 1 |
| 74 | 5.4×10 | 1 |
| 75 | 500,000/microl | 1 |
| 76 | 54/146 | 1 |
| 77 | 5in | 1 |
| 78 | 5mgg | 1 |
| 79 | 6.0mmol | 1 |
| 80 | 60minutes | 1 |
| 81 | 62å | 1 |
| 82 | 6300-8400 | 1 |
| 83 | 6300-base | 1 |
| 84 | 7.0μgl | 1 |
| 85 | 74mbq | 1 |
| 86 | 9.3/1 | 1 |
| 87 | 9.6-times | 1 |
| 88 | 90/1000 | 1 |
| 89 | afterthoughts | 1 |
| 90 | ayu-nephro-tone | 1 |
| 91 | birth-weights | 3 |
| 92 | bisects | 1 |
| 93 | body/self | 1 |
| 94 | chews/all | 1 |
| 95 | circosan | 2 |
| 96 | co-signing | 1 |
| 97 | control/coping | 1 |
| 98 | coping/control | 1 |
| 99 | cuanzu | 1 |
| 100 | cytokines-of | 1 |
| 101 | deride | 1 |
| 102 | digestin | 5 |
| 103 | dose-proportionately | 1 |
| 104 | doubling | 836 |
| 105 | eight-times | 1 |
| 106 | eqalled | 1 |
| 107 | familiarities | 1 |
| 108 | five-days | 8 |
| 109 | four-fifths | 17 |
| 110 | gbp350 | 1 |
| 111 | glorify | 1 |
| 112 | groups.although | 1 |
| 113 | gut-representation | 1 |
| 114 | half | 7,488 |
| 115 | halving | 51 |
| 116 | harm-fullness | 1 |
| 117 | hydrovinylation | 4 |
| 118 | insufflate | 1 |
| 119 | job-demand | 1 |
| 120 | kosta | 1 |
| 121 | lenghthening | 1 |
| 122 | limac | 1 |
| 123 | mean-2.0 | 1 |
| 124 | miserably | 1 |
| 125 | mistiming | 3 |
| 126 | mr-images | 1 |
| 127 | new-users | 1 |
| 128 | nondissociable | 1 |
| 129 | nonrefrigerated | 1 |
| 130 | one-fifth | 125 |
| 131 | one-fourth | 94 |
| 132 | one-half | 355 |
| 133 | one-hundredth | 1 |
| 134 | one-quarter | 139 |
| 135 | one-seventh | 4 |
| 136 | one-sixth | 20 |
| 137 | one-tenth | 30 |
| 138 | one-third | 1,119 |
| 139 | one-thirds | 1 |
| 140 | one-thirtieth | 1 |
| 141 | phenytoin.for | 1 |
| 142 | placebo-this | 1 |
| 143 | placebo.sumatriptan | 1 |
| 144 | placebo.trials | 1 |
| 145 | pm-release | 1 |
| 146 | positions.as | 1 |
| 147 | pound18 | 1 |
| 148 | pseudo-doctoring | 1 |
| 149 | pseudorelationships | 1 |
| 150 | qualitatively.12 | 1 |
| 151 | qualitatively.9 | 1 |
| 152 | qualitatively.six | 1 |
| 153 | questions-including | 1 |
| 154 | re-reading | 3 |
| 155 | recouping | 2 |
| 156 | rs1048943/cyp1a1 | 1 |
| 157 | salak | 1 |
| 158 | scientification | 4 |
| 159 | seven-tenths | 1 |
| 160 | some-of | 1 |
| 161 | squandering | 3 |
| 162 | st£12.38 | 1 |
| 163 | tanezumab+nsaids | 1 |
| 164 | test-positives | 1 |
| 165 | thermisation | 3 |
| 166 | three-fifths | 8 |
| 167 | three-fourth | 7 |
| 168 | three-fourths | 39 |
| 169 | three-quarter | 10 |
| 170 | three-quarters | 122 |
| 171 | time-end-diastolic | 1 |
| 172 | tpmsc | 2 |
| 173 | two-fifths | 8 |
| 174 | two-third | 25 |
| 175 | two-thirds | 713 |
| 176 | ward-and | 1 |
| 177 | zncl2/hzsm-5 | 1 |
| 178 | £104 | 1 |
| 179 | £288,600 | 1 |
| 180 | £3,000 | 1 |
| 181 | £62,500 | 1 |
| 182 | £6200 | 1 |
| 183 | £830 | 1 |
| 184 | épidémiology | 1 |
| 185 | δcortisol | 5 |
| 186 | π/6 | 1 |
| 187 | €1100 | 1 |
| 188 | €68,000 | 1 |
| 1 | 3n+ | 3 |
| 2 | -12. | 1 |
| 3 | -1/ | 1 |
| 4 | mean-2.0 | 1 |
| 5 | 1,200-2,000 | 1 |
| 6 | £3,000 | 1 |
| 7 | 144,000 | 1 |
| 8 | 128,000 | 1 |
| 9 | €68,000 | 1 |
| 10 | 90/1000 | 1 |
| 11 | 29000 | 1 |
| 12 | 1:9000 | 1 |
| 13 | €1100 | 1 |
| 14 | £6200 | 1 |
| 15 | 14400 | 1 |
| 16 | 6300-8400 | 1 |
| 17 | £62,500 | 1 |
| 18 | 1:13,500 | 1 |
| 19 | 20/1500 | 1 |
| 20 | £288,600 | 1 |
| 21 | 300x10 | 1 |
| 22 | 5.4×10 | 1 |
| 23 | 1/20-1/30 | 1 |
| 24 | £830 | 1 |
| 25 | 12:00-13:30 | 1 |
| 26 | gbp350 | 1 |
| 27 | 24,680 | 1 |
| 28 | 204/690 | 1 |
| 29 | 2.5-to-1 | 1 |
| 30 | 9.3/1 | 1 |
| 31 | rs1048943/cyp1a1 | 1 |
| 32 | qualitatively.12 | 1 |
| 33 | 1.545-3.523 | 1 |
| 34 | 0.1563 | 1 |
| 35 | £104 | 1 |
| 36 | zncl2/hzsm-5 | 1 |
| 37 | 49,605 | 1 |
| 38 | 3,955 | 2 |
| 39 | π/6 | 1 |
| 40 | 18.34±4.36 | 1 |
| 41 | 54/146 | 1 |
| 42 | 15,346 | 3 |
| 43 | 171/187 | 1 |
| 44 | pound18 | 1 |
| 45 | st£12.38 | 1 |
| 46 | qualitatively.9 | 1 |
| 47 | kosta | 1 |
| 48 | 10lb | 1 |
| 49 | 44.1-mb | 1 |
| 50 | 2.2mb | 1 |
| 51 | limac | 1 |
| 52 | time-end-diastolic | 1 |
| 53 | tpmsc | 2 |
| 54 | 148°c | 1 |
| 55 | eqalled | 1 |
| 56 | nonrefrigerated | 1 |
| 57 | 3900-fold | 1 |
| 58 | 1.73-fold | 2 |
| 59 | 2.5-5-fold | 1 |
| 60 | 14.6-fold | 1 |
| 61 | 1½-fold | 1 |
| 62 | ward-and | 1 |
| 63 | job-demand | 1 |
| 64 | one-third | 1,119 |
| 65 | two-third | 25 |
| 66 | deride | 1 |
| 67 | 22-nucleotide | 1 |
| 68 | nondissociable | 1 |
| 69 | ayu-nephro-tone | 1 |
| 70 | 6300-base | 1 |
| 71 | pm-release | 1 |
| 72 | insufflate | 1 |
| 73 | 200-bite | 1 |
| 74 | half | 7,488 |
| 75 | one-half | 355 |
| 76 | body/self | 1 |
| 77 | some-of | 1 |
| 78 | cytokines-of | 1 |
| 79 | 5mgg | 1 |
| 80 | re-reading | 3 |
| 81 | questions-including | 1 |
| 82 | doubling | 836 |
| 83 | mistiming | 3 |
| 84 | lenghthening | 1 |
| 85 | co-signing | 1 |
| 86 | control/coping | 1 |
| 87 | recouping | 2 |
| 88 | squandering | 3 |
| 89 | pseudo-doctoring | 1 |
| 90 | halving | 51 |
| 91 | groups.although | 1 |
| 92 | 1/1,000th | 1 |
| 93 | 1/40th | 1 |
| 94 | 3/4th | 3 |
| 95 | one-hundredth | 1 |
| 96 | one-thirtieth | 1 |
| 97 | one-fifth | 125 |
| 98 | one-tenth | 30 |
| 99 | one-seventh | 4 |
| 100 | three-fourth | 7 |
| 101 | one-fourth | 94 |
| 102 | one-sixth | 20 |
| 103 | salak | 1 |
| 104 | 1.8g/l | 2 |
| 105 | 133mg/l | 1 |
| 106 | 2.1-mg/dl | 1 |
| 107 | 1.4-mg/dl | 1 |
| 108 | 7.0μgl | 1 |
| 109 | chews/all | 1 |
| 110 | 1.1mg/ml | 1 |
| 111 | 30µg/ml | 2 |
| 112 | 10iu/ml | 1 |
| 113 | 250pgml | 1 |
| 114 | 6.0mmol | 1 |
| 115 | 500,000/microl | 1 |
| 116 | coping/control | 1 |
| 117 | δcortisol | 5 |
| 118 | 0.4μg/m | 1 |
| 119 | 22mm | 1 |
| 120 | 2mm×5mm | 1 |
| 121 | 27mm | 1 |
| 122 | circosan | 2 |
| 123 | placebo.sumatriptan | 1 |
| 124 | 5in | 1 |
| 125 | digestin | 5 |
| 126 | scientification | 4 |
| 127 | hydrovinylation | 4 |
| 128 | thermisation | 3 |
| 129 | gut-representation | 1 |
| 130 | 'distinction | 1 |
| 131 | 3-log-reduction | 1 |
| 132 | 3500bp | 1 |
| 133 | 74mbq | 1 |
| 134 | 0.6-0.8/1000/year | 1 |
| 135 | 1°/year | 1 |
| 136 | three-quarter | 10 |
| 137 | one-quarter | 139 |
| 138 | phenytoin.for | 1 |
| 139 | 2-5s | 1 |
| 140 | positions.as | 1 |
| 141 | tanezumab+nsaids | 1 |
| 142 | 3-folds | 1 |
| 143 | 2/3rds | 2 |
| 144 | one-thirds | 1 |
| 145 | two-thirds | 713 |
| 146 | mr-images | 1 |
| 147 | familiarities | 1 |
| 148 | 1.5log10cycles | 1 |
| 149 | 3.5log10cycles | 1 |
| 150 | 9.6-times | 1 |
| 151 | eight-times | 1 |
| 152 | 60minutes | 1 |
| 153 | test-positives | 1 |
| 154 | 1,3-dags | 3 |
| 155 | three-fifths | 8 |
| 156 | two-fifths | 8 |
| 157 | four-fifths | 17 |
| 158 | seven-tenths | 1 |
| 159 | 4.5months | 1 |
| 160 | 15months | 3 |
| 161 | three-fourths | 39 |
| 162 | placebo-this | 1 |
| 163 | 26weeks | 3 |
| 164 | placebo.trials | 1 |
| 165 | pseudorelationships | 1 |
| 166 | 40years | 8 |
| 167 | new-users | 1 |
| 168 | three-quarters | 122 |
| 169 | harm-fullness | 1 |
| 170 | bisects | 1 |
| 171 | birth-weights | 3 |
| 172 | afterthoughts | 1 |
| 173 | five-days | 8 |
| 174 | 22.2ghz/refractive-index-unit | 1 |
| 175 | 'about | 2 |
| 176 | cuanzu | 1 |
| 177 | 37w | 1 |
| 178 | 1-4pw | 1 |
| 179 | qualitatively.six | 1 |
| 180 | 2gr/day | 2 |
| 181 | 21day | 1 |
| 182 | glorify | 1 |
| 183 | 100-190mgy | 1 |
| 184 | épidémiology | 1 |
| 185 | miserably | 1 |
| 186 | dose-proportionately | 1 |
| 187 | 5-month-history | 1 |
| 188 | 62å | 1 |